News
Explore how Life Sciences Ireland will champion the growth and global presence of Ireland's life sciences sectors. From cutting-edge training in entrepreneurship and business acceleration to impactful initiatives that elevate and promote the industry at home and abroad—this is your hub for updates, insights, and success stories.
How the EMA Supports Innovation in Medicine Development
Europe's life sciences sector is undergoing rapid transformation, driven by scientific advances, new therapeutic modalities, and evolving patient needs. At the centre of this progress is the European Medicines Agency (EMA), whose regulatory frameworks and innovation‑focused supports help developers bring safe, effective medicines to patients with greater speed and confidence. For organisations across Ireland's life sciences ecosystem, understanding these supports is essential to accelerating discovery, development, and delivery.
The EMA's Role in Enabling Innovation
The EMA provides a structured environment that helps innovators navigate complex regulatory pathways while maintaining the highest standards of quality, safety, and efficacy. Through early engagement, scientific guidance, and tailored programmes for emerging companies, the Agency ensures that promising technologies can progress efficiently from concept to clinical reality.
Key mechanisms that strengthen innovation include:
• Innovation Task Force (ITF) Briefing Meetings — Early‑stage dialogue for developers working on novel technologies, advanced therapies, digital health tools, and other cutting‑edge approaches. These sessions help clarify regulatory expectations and identify potential development pathways.
• Scientific Advice and Qualification of New Methodologies — Expert guidance that supports developers in designing robust studies, validating new tools or biomarkers, and ensuring that evidence generation aligns with regulatory standards.
• Targeted Support for SMEs — Dedicated assistance for micro, small, and medium‑sized enterprises, helping them navigate regulatory processes, understand data requirements, and access tailored resources that reduce barriers to innovation.
These supports are complemented by broader initiatives such as the EMA's Regulatory Science Strategy and Europe's evolving pharmaceutical legislation, both of which aim to modernise regulatory science and strengthen Europe's position as a global leader in health innovation.
Strengthening Ireland's Life Sciences Ecosystem
Ireland's life sciences sector—spanning pharmaceuticals, biopharma, MedTech, diagnostics, digital health, and advanced manufacturing—relies on strong regulatory partnerships to remain globally competitive. The EMA's innovation pathways provide clarity and momentum for academic researchers, start‑ups, scale‑ups, and established industry leaders seeking to advance breakthrough therapies and technologies.
At Life Sciences Ireland, we champion the organisations shaping the future of healthcare. Leveraging the EMA's innovation supports is a critical step in accelerating next‑generation medicines, enhancing regulatory readiness, and ensuring Ireland remains a strategic hub for global development and manufacturing.
The future of medicine is arriving quickly. Ireland intends to be at the centre of it.
Europe Sustainable Development Report 2026: What It Means for the Life Sciences Sector in Ireland and Across Europe
The seventh edition of the Europe Sustainable Development Report (ESDR2026) has been released, offering the most comprehensive assessment to date of Europe's progress toward the UN Sustainable Development Goals (SDGs). While Europe continues to lead globally on sustainable development, the report highlights a clear slowdown in momentum, with several goals showing stagnation or reversal.
For Europe's life sciences sector — and for Ireland as one of its strongest and most export‑driven hubs — the findings carry important strategic implications.
Europe's Position: Leadership Under Pressure
The ESDR2026 reaffirms that European countries remain the strongest global performers on sustainable development. However, the report also points to a shift in political priorities, reduced emphasis on the SDGs in EU‑level policy frameworks, and growing geopolitical and economic pressures. These include:
• Dilution of elements of the European Green Deal.
• Increased defence spending diverting resources from sustainability initiatives.
• Slower economic growth compared with other advanced economies.
• Fragmentation in capital markets limiting investment in green and digital technologies.
For a sector that depends on regulatory stability, long‑term investment, and global collaboration, these trends present both risks and opportunities.
Implications for Europe's Life Sciences Sector
The life sciences industry sits at the intersection of health, innovation, sustainability, and advanced manufacturing. The ESDR2026 highlights several areas where the sector will be directly affected:
• Rising expectations for sustainability performance across supply chains, manufacturing, and product lifecycles.
• Greater scrutiny of environmental and social impacts, driven by investors, regulators, and global markets.
• Increasing importance of high‑quality, disaggregated data, aligning with the report's emphasis on transparency and measurement.
• Pressure to maintain competitiveness as Europe faces slower growth and intensifying global competition in biotech, medtech, and digital health.
These dynamics reinforce the need for coordinated action across industry, government, and academia.
Ireland's Position: Strong Foundations, Emerging Challenges
Ireland consistently ranks among Europe's top performers on sustainable development, benefiting from a highly educated workforce, strong industrial clusters, and a globally connected life sciences ecosystem. However, the ESDR2026 makes clear that continued progress cannot be taken for granted.
For Ireland's life sciences sector, three priorities stand out:
• Accelerating decarbonisation in manufacturing and logistics, particularly in energy‑intensive biopharma and medtech operations.
• Strengthening talent pipelines and inclusion, aligning with the SDG commitment to "leave no one behind" and addressing skills shortages in advanced manufacturing, digitalisation, and regulatory science.
• Deepening collaboration across Europe, especially in research, regulatory alignment, and sustainable innovation, as geopolitical shifts reshape global partnerships.
Ireland's ability to lead in sustainable life sciences will depend on maintaining its reputation for innovation, reliability, and long‑term strategic vision.
A Call for Renewed Leadership
The ESDR2026 underscores that sustainable development and industrial competitiveness are now inseparable. For Europe — and for Ireland — the life sciences sector has a central role to play in advancing both.
Life Sciences Ireland will continue to support industry partners, policymakers, and research institutions in driving sustainable innovation, strengthening Ireland's global leadership, and ensuring that the sector remains resilient and future‑focused as Europe navigates the path to 2030 and beyond.
Global life sciences: Key developments shaping 2026
The global life sciences landscape is moving at extraordinary pace, with a series of high‑impact developments emerging in early 2026. From AI‑driven discovery platforms to breakthroughs in gene editing and synthetic biology, the sector is entering a new phase of convergence between data, engineering, and biology.
For Ireland—already a recognised global hub for biopharma, MedTech, and advanced manufacturing—these shifts present both opportunity and urgency. Life Sciences Ireland is tracking these trends closely to help industry, academia, and policymakers align around the next wave of innovation and investment.
AI as core scientific infrastructure
Artificial intelligence is rapidly evolving from a support tool to core scientific infrastructure in leading biopharma organisations. One of the most notable signals is Eli Lilly's partnership with NVIDIA to build a molecular simulation supercomputer, designed to accelerate drug discovery and development by enabling large‑scale modelling of molecular interactions.
This marks a decisive shift in how R&D is conceived:
• From incremental to systemic: AI is now embedded across target identification, lead optimisation, and clinical trial design.
• From siloed tools to integrated platforms: High‑performance computing, advanced analytics, and real‑world data are being combined into unified discovery engines.
For Ireland, with its strong base in digital manufacturing, data science, and regulatory excellence, this presents a strategic opportunity to:
• Attract AI‑enabled R&D investments
• Deepen collaborations between pharma, MedTech, and Ireland's universities
• Build talent pipelines that blend computational and life sciences skills
Life Sciences Ireland is actively engaging with stakeholders to ensure our national ecosystem is positioned to participate in—and help shape—this AI‑driven transformation.
Breakthroughs in gene editing and repeat expansion disorders
Following landmark progress in slowing Huntington's disease in 2025, global attention is turning to the broader class of repeat expansion disorders. Enabled by advances in long‑read sequencing and precision gene editing, researchers are now exploring new therapeutic strategies for conditions that were previously considered intractable.
Key dynamics include:
• Rising investment in cell and gene therapies: Capital and partnerships are flowing into platforms that can be adapted across multiple rare and complex diseases.
• Improved understanding of disease mechanisms: High‑resolution genomic tools are revealing new targets and pathways for intervention.
Ireland's ecosystem—spanning biopharma manufacturing, clinical research, and specialist academic centres—is well placed to contribute to this emerging wave of therapies. There is particular potential to:
• Expand clinical trial activity in advanced therapeutics
• Build specialised manufacturing capabilities for cell and gene therapies
• Develop training programmes to equip the workforce for these highly specialised modalities
Life Sciences Ireland is working with partners to map capability gaps and opportunities, ensuring Ireland can play a meaningful role in the global gene therapy landscape.
Synthetic biology and bioengineering accelerate
Synthetic biology is moving from promise to implementation, with companies now engineering microbes to produce complex medicines, designing programmable cell therapies, and developing next‑generation vaccines and biologics.
This convergence of biology and engineering is reshaping multiple domains:
• Medicine: Smarter, more targeted therapies and vaccine platforms
• Sustainability: Bio‑based production routes for materials and chemicals
• Manufacturing: New bioprocesses that demand flexible, digitally enabled facilities
Ireland's established strength in bioprocessing and biologics manufacturing provides a strong foundation to lead in scalable, next‑generation production. Strategic priorities include:
• Upgrading facilities and skills for modular, flexible biomanufacturing
• Encouraging collaboration between bioengineers, data scientists, and process experts
• Supporting start‑ups and scale‑ups working at the interface of synthetic biology and industrial biotechnology
Through coordinated cluster activity, Life Sciences Ireland aims to connect these capabilities and accelerate Ireland's role in this rapidly advancing field.
Ireland's opportunity in a changing global landscape
Taken together, these global developments point to a life sciences sector that is:
• More data‑driven and AI‑enabled
• More personalised and precise in its therapies
• More integrated across disciplines and geographies
For Ireland, the challenge and opportunity lie in moving quickly and collaboratively:
• Industry: Continue to invest in advanced manufacturing, digital transformation, and R&D capabilities.
• Academia: Expand interdisciplinary programmes that blend life sciences, data, and engineering.
• Government and agencies: Align policy, infrastructure, and talent strategies with the next wave of global demand.
Life Sciences Ireland is committed to acting as a national convenor—bringing together companies, universities, training providers, and policymakers to ensure Ireland not only keeps pace with global change, but helps lead it.
Get involved
Life Sciences Ireland will be hosting a series of engagement days and thematic workshops focused on:
• AI and digital transformation in life sciences
• Advanced therapeutics and gene‑based medicines
• Next‑generation bioprocessing and synthetic biology
Organisations interested in contributing to these discussions, showcasing capabilities, or shaping Ireland's future life sciences strategy are invited to connect with us.
Together, we can build the next chapter of Ireland's life sciences success—anchored in innovation, collaboration, and global impact.
Spanish Breakthrough in Pancreatic Cancer Research Underscores Ireland's Opportunity to Lead in Life Sciences Innovation
A major scientific development in Spain has captured international attention and reignited discussion about how countries can accelerate life‑changing biomedical innovation. Researchers at the Spanish National Cancer Research Centre (CNIO), led by Dr. Mariano Barbacid, have reported the complete elimination of pancreatic tumours in mice using a novel triple‑drug therapy targeting the KRAS pathway — one of the most challenging and lethal mechanisms in oncology.
While the findings remain preclinical and have not yet been tested in humans, the achievement represents a significant milestone in cancer research. The therapy works by simultaneously blocking three critical signalling nodes within the KRAS pathway, preventing tumours from developing resistance — a barrier that has historically limited progress in pancreatic cancer treatment.
This breakthrough is more than a scientific success. It is a powerful demonstration of what becomes possible when world‑class research, translational focus, and commercial ambition operate in alignment.
Implications for Ireland's Life Sciences Sector
Ireland is already recognised globally for excellence in biopharmaceutical manufacturing, MedTech innovation, and clinical capability. Yet breakthroughs of this scale challenge us to think bigger — to build an ecosystem capable not only of supporting innovation, but of generating it.
To fully seize this opportunity, Ireland must advance in four key areas:
1. Deep, Sustained Investment in Translational Research
Breakthroughs like the KRAS triple‑therapy are the result of decades of foundational science.
Ireland's universities and research centres have the talent and expertise; long‑term funding models and stronger industry partnerships are essential to unlock their full potential.
2. Stronger Clinical Trial Infrastructure
Preclinical success is only the first step.
Ireland can position itself as a preferred global location for early‑phase oncology trials by expanding trial capacity, streamlining regulatory pathways, and deepening collaboration between hospitals, clinicians, and industry partners.
3. A National Framework for Life Sciences Commercialisation
The Spanish research team has already moved to patent and commercialise their approach.
Ireland needs a unified national strategy that accelerates IP translation, supports spin‑outs, and connects researchers with investors and global partners to bring discoveries to market.
4. A Connected, Cluster‑Driven Ecosystem
The future belongs to countries that integrate research, clinical practice, manufacturing, and commercialisation into a single coordinated engine.
Ireland is uniquely positioned to build such a model — and Life Sciences Ireland is committed to driving this vision forward.
Ireland Can Deliver Breakthroughs of Global Significance
The Spanish achievement is not just a scientific milestone — it is a signal.
A signal that transformational innovation is possible.
A signal that countries willing to invest boldly in science, talent, and collaboration will shape the future of global healthcare.
- Ireland has the talent.
- Ireland has the industry.
- Ireland has the ambition.
Now is the moment to build the next generation of life sciences leadership — together.
A Defining Moment for European Life Sciences — What It Means for Ireland
Insights & Perspective from Life Sciences Ireland
Europe's life sciences sector is entering a pivotal decade. As highlighted in Politico's recent feature "A Defining Moment for European Life Sciences", the continent faces a strategic crossroads: global competitors are accelerating investment, modernising regulation, and building long‑term industrial strategies at a pace Europe has yet to match.
At the same time, Europe retains extraordinary strengths — world‑class scientific institutions, a highly skilled workforce, and a globally significant biopharma and MedTech manufacturing base. The challenge now is to convert these strengths into sustained leadership in the next generation of health innovation.
Key Themes Shaping Europe's Future
The article underscores several critical issues that will define Europe's competitiveness:
⚖️ Regulatory Modernisation
Europe's regulatory frameworks must evolve to keep pace with scientific and technological breakthroughs. Faster, more adaptive pathways are essential to ensure that innovation reaches patients without unnecessary delay.
💶 Investment & Industrial Strategy
Global competitors are deploying large‑scale, coordinated investment strategies. Europe must respond with ambition — strengthening incentives, supporting advanced manufacturing, and ensuring that innovation can scale.
🤝 Collaboration Across the Ecosystem
The future belongs to ecosystems that work together. The article emphasises the need for deeper alignment between industry, academia, and policymakers to accelerate discovery, development, and deployment.
🧭 A Decisive Decade
The next ten years will determine whether Europe remains a global leader in life sciences or cedes ground to faster‑moving regions.
Why This Matters for Ireland
Ireland is one of Europe's most successful life sciences hubs — a trusted manufacturing base, a centre of scientific excellence, and a gateway for global innovators. But Ireland is not insulated from the pressures facing Europe.
To secure our position, Ireland must help shape Europe's response. That means:
• Championing regulatory reform that supports innovation
• Strengthening Ireland's voice in EU‑level policy discussions
• Investing in skills, infrastructure, and advanced technologies
• Deepening collaboration across industry, academia, and government
• Positioning Ireland as a model for agile, innovation‑ready ecosystems
Life Sciences Ireland's Commitment
Life Sciences Ireland is dedicated to supporting a strong, globally connected, and future‑focused sector. We are committed to:
• Convening national and international stakeholders
• Supporting cluster development and regional growth
• Promoting Ireland's leadership in advanced manufacturing and emerging therapeutics
• Advocating for policies that strengthen Europe's competitiveness
• Building the talent and innovation capacity required for long‑term success
Europe's defining moment is also Ireland's. With coordinated action and bold ambition, Ireland can help shape a stronger, more competitive European life sciences landscape — one that continues to deliver transformative health solutions for patients worldwide.
🚨 EU Agrees Landmark Reform of Pharmaceutical Legislation
On 11 December 2025 — The European Union has reached a historic agreement on a new pharmaceutical package, marking a milestone in the modernisation of Europe's life sciences framework. The deal, struck between the EU Council and European Parliament, forms a central pillar of the EU Life Sciences Strategy and sets the stage for a more agile, innovative, and patient-focused sector.
🎯 Objectives of the Reform
The package is designed to:
✅ Ensure fast, fair, and safe access to medicines
✅ Streamline EMA processes and reduce regulatory burdens
✅ Strengthen security of supply and address shortages
✅ Incentivise innovation in orphan medicines, antimicrobials, and breakthrough therapies
✅ Clarify the Bolar exemption to support timely entry of generics
🔑 Key Highlights
•Regulatory Data Protection: 8 years retained for new medicines, with conditional extensions up to 11 years for orphan drugs.
•Faster EMA Evaluations: Review timelines reduced from 210 to 180 days, with unlimited marketing authorisations in most cases.
• Supply Security: Mandatory shortage prevention plans and EU-wide monitoring of critical medicines.
• Innovation Boost: Introduction of regulatory sandboxes to foster novel therapies.
🌍 Strategic Impact
While final texts are still awaited, this agreement signals the EU's determination to position Europe as the world's most attractive hub for life sciences by 2030.
At Life Sciences Ireland, we welcome this landmark step forward. It strengthens the environment for innovation, collaboration, and competitiveness—ensuring Ireland's life sciences sector continues to thrive as part of a globally connected ecosystem.
💬 Join the Conversation
How do you see these reforms shaping industry behaviour and patient access in the years ahead?
📌 Contact Life Sciences Ireland
🌐 Visit us online
📧 info@lifesciencesireland.ie
☎️ +353-21-4928944
Lilly's $3 Billion Investment in Leiden: A Case Study in Cluster Excellence
Eli Lilly and Company has announced plans to build a $3 billion oral medicine manufacturing facility in Katwijk, Netherlands, within the renowned Leiden Bio Science Park. This strategic investment will create 500 high-value manufacturing roles and 1,500 construction jobs, while significantly expanding Lilly's European supply chain capacity.
Leiden's selection was no accident. The region's success reflects the power of a mature life sciences ecosystem and deliberate cluster policy. Lilly cited several decisive factors in its choice:
• Access to a highly skilled workforce, supported by strong academic and research institutions
• Advanced infrastructure and manufacturing capabilities, including dock-to-dock automation and paperless production
• A predictable, innovation-friendly policy environment, shaped by close collaboration between government, academia, and industry
• Operational synergies and supply chain flexibility, enabled by proximity to other European manufacturing sites
• Commitment to sustainability, with carbon-neutral operations and zero waste to landfill
This investment also marks a milestone in Lilly's global strategy to manufacture and distribute medicines closer to the communities they serve. The new facility will produce orforglipron, Lilly's first oral GLP-1 receptor agonist, among other advanced therapies in cardiometabolic health, neuroscience, oncology, and immunology.
For Ireland, the message is clear: Leiden's success is the result of long-term strategic planning, integrated cluster development, and policy alignment. As we continue to build our own life sciences clusters, there is much to learn from the Dutch model. Life Sciences Ireland remains committed to fostering an environment where innovation, talent, and collaboration can thrive—positioning Ireland as a global leader in life sciences excellence.
Ireland is being urged to accelerate reforms to its clinical trials system.
A recent Euractiv article highlights growing concern over Ireland's slow progress in reforming its clinical trials infrastructure, despite the EU Clinical Trials Regulation (CTR) aiming to streamline processes across member states. While the CTR has improved transparency and harmonisation, Ireland still faces significant delays in trial start-up times, placing it behind countries like Belgium and Spain.
Key points include:
• Ireland ranks 20th out of 30 EU/EEA countries for clinical trial application timelines, with average approval taking over 100 days—well above the EU target of 60 days.
• Stakeholders cite fragmented governance, under-resourced ethics committees, and a lack of digital infrastructure as major barriers.
• Industry leaders warn that Ireland risks losing investment and trial opportunities to faster-moving EU countries unless urgent reforms are made.
• The Health Research Board (HRB) and Department of Health are working on a national strategy, but timelines remain unclear.
• Calls for action include establishing a single national ethics committee, investing in digital systems, and creating a centralised clinical trials office.
For Life Sciences Ireland, this moment underscores the urgent need for coordinated national leadership, investment in infrastructure, and streamlined governance to ensure Ireland remains a competitive and attractive destination for clinical research. As a cluster committed to advancing innovation and collaboration, we echo the call for swift, strategic action to unlock Ireland's full potential in the global clinical trials landscape.
For updates on upcoming initiatives and stakeholder engagement, visit lifesciencesireland.ie or follow us on LinkedIn.
Life Sciences Ireland Cluster: Driving All-Island Innovation at TCI Global Conference 2025- Oct 14th to Oct 16th
Dublin, October 16, 2025 — The Life Sciences Ireland cluster proudly participated in the 25th TCI Global Conference, held from October 14–16 at the Dublin Royal Convention Centre. Hosted jointly by InterTradeIreland, Invest Northern Ireland, and Enterprise Ireland under the Shared Island Enterprise Scheme, the event marked a historic first: an all-island collaboration spotlighting Ireland's leadership in cluster development.
With over 300 delegates from around the world, the conference explored the theme "Clusters: Sustaining a Global Open Economy," and positioned life sciences as a cornerstone of innovation, resilience, and international connectivity.
🔬 Day 1: Setting the Vision for Cluster-Led Growth
The opening day focused on the strategic role of clusters in building competitive and sustainable economies. Life Sciences Ireland joined discussions on how health and life sciences clusters can drive productivity, innovation, and inclusive growth. The cluster's presence underscored Ireland's commitment to ecosystem thinking and cross-sector collaboration.
🌐 Day 2: Strengthening Global and All-Island Partnerships
Day two emphasized international connectivity and the power of clusters to attract Foreign Direct Investment (FDI). Life Sciences Ireland contributed to sessions on scaling biotech and medtech innovation, showcasing Ireland's strengths in translational research, talent development, and shared infrastructure. The cluster's cross-border model was highlighted as a blueprint for collaborative excellence.
💡 Day 3: Health Innovation as a Catalyst for Change
The final day spotlighted health and life sciences as engines of economic transformation. Life Sciences Ireland participated in breakout sessions focused on accelerating health innovation, fostering industry-academic-government partnerships, and building globally connected ecosystems. The cluster's role in shaping Ireland's future as a life sciences leader was front and centre.
🚀 Looking Ahead
The TCI Global Conference 2025 was more than a gathering—it was a launchpad for future growth. Life Sciences Ireland leaves the event energized, with new partnerships, strategic insights, and a shared vision for building a world-class, internationally connected life sciences ecosystem across the island.
For updates on upcoming initiatives and stakeholder engagement, visit lifesciencesireland.ie or follow us on LinkedIn.
🔬 Life Sciences Ireland at the Tri-Region Partnership Autumn 2025 – Driving Innovation Across Borders 🌍
We're proud to represent the Life Sciences Cluster Ireland at this year's Tri-Region Partnership Autumn 2025, held in Cork on 18–19 September. This dynamic event brings together leaders from Cork, Dublin, and Northern Ireland to foster collaboration across enterprise, innovation, infrastructure, and education.
📍 Highlights from the agenda:
➤Engaging sessions on Connecting People & Places with insights from Irish Rail, Cork Airport, and Docklands Development.
➤A powerful panel on Enterprise, Innovation & Industry featuring Qualcomm, IDA Ireland, Invest NI, and Enterprise Ireland.
➤A deep dive into Our Maritime Future at the National Maritime College of Ireland, showcasing the MaREI Centre and Port of Cork.
➤A forward-looking discussion on Innovation Clusters & Education at University College Cork, where Life Sciences Ireland joined HIRANI to spotlight sectoral collaboration and shared opportunities.
🤝 The Tri-Region Partnership is a testament to the strength of regional cooperation and the potential of cross-border innovation. Life Sciences Ireland is committed to advancing this mission—connecting talent, research, and industry to shape a healthier, more sustainable future.
Thank you to our hosts at Cork Chamber, UCC, NMCI, and all partners involved. We look forward to building on the momentum and continuing the conversation.
Ireland's Life Sciences Sector Poised for Growth Under New Government Action Plan
10 September 2025 – Dublin, Ireland
The Irish Government has published its Action Plan on Competitiveness and Productivity, a forward-looking strategy designed to strengthen Ireland's economic resilience and global standing over the next five years. With 85 targeted actions, including 26 priority measures, the plan aims to address challenges posed by global uncertainty, technological disruption, and infrastructure bottlenecks.
For Ireland's Life Sciences sector, the plan presents a transformative opportunity to accelerate innovation, attract investment, and scale enterprise growth.
Key Implications for Life Sciences
🔬 Innovation & Research Funding
The plan outlines a "step change" in funding for innovation, with a strong emphasis on collaboration between industry and higher education institutions. This will reinforce Ireland's R&D ecosystem—vital for biotech, medtech, and pharmaceutical advancement.
🌍 Boosting FDI & Global Influence
Ireland's commitment to attracting high-value foreign direct investment (FDI) and influencing EU competitiveness policy will help maintain its leadership position in global life sciences.
🏗️ Infrastructure & Regulatory Reform
Accelerated infrastructure delivery and streamlined regulatory processes will enable life sciences companies to scale more efficiently and navigate planning and compliance with greater ease.
💡 Digital & AI Integration
New frameworks for artificial intelligence and intellectual property will support the sector's digital transformation, fostering smarter manufacturing, diagnostics, and data-driven healthcare solutions.
📈 SME Scaling & Talent Development
The plan includes support for SME scaling funds, tax incentives, and workforce upskilling—empowering emerging life sciences innovators to grow and compete on a global stage.
A Vision for 2030
With a national goal of creating 300,000 new jobs by 2030, the life sciences sector is positioned to play a central role in shaping a more agile, innovation-led economy. The challenge now lies in implementation—ensuring these ambitions translate into tangible outcomes for businesses, researchers, and patients.
📄 Read the full Action Plan:
gov.ie – Action Plan on Competitiveness and Productivity
Life Sciences Ireland to Spotlight Innovation at Tech Industry Alliances Event-Sept 30th
Life Sciences Ireland is proud to participate in the upcoming Tech Industry Alliances event, Transforming Life Sciences: The Power of AI & Emerging Tech, taking place on September 30th. This dynamic gathering will explore how artificial intelligence and cutting-edge technologies are reshaping the future of healthcare, biotechnology, and pharmaceutical innovation. Life Sciences Ireland will join industry leaders, researchers, and tech pioneers on sector specific panels to showcase collaborative efforts driving transformative change across the sector.
Some key been presented and discussed during the event include,
- AI in Life Sciences Unlocking the Next Frontier of Medicine Manufacturing
- Smarter, Faster, Safer: How Tech is Reinventing the Life Sciences Sector"
- Supports working at the intersection of AI, life sciences and digital health
We look forward to meeting sector peers & entrepreneurs from small, medium and large organizations during this timely event run by Tech Industry Alliances and Deloitte.
🚀 Boosting Biotech Through Innovation Clusters: Lessons for Ireland from Flanders
Written by: Nicole Verbeeck Euractiv Health Capitals
At the recent Knowledge for Growth conference, the European Commission spotlighted Flanders' Biovia cluster as a model for driving biotech innovation.
With its integrated approach across biotech, health tech, agtech, and biomanufacturing, Biovia is setting a new standard for regional innovation ecosystems.
🇪🇺 Rainer Becker (European Commission - DG COMP) emphasized the need to connect successful clusters across Europe to enhance competitiveness, while Flemish leaders called for smarter regulation, streamlined support, and better funding for scale-ups.
Key takeaways:
🧬 Clusters like Biovia offer agility, integration, and a single point of contact for innovators.
💡 Innovation must translate into real-world impact—healthier lives, sustainable agriculture, and environmental solutions.
⏱️ Urgency is critical: Europe must simplify regulation and accelerate adoption of new technologies.
💶 Funding gaps, especially for scale-ups, remain a major hurdle.
📣 As Europe shapes its Biotech Act, it's time to learn from regional success stories—and act fast.
Article✍️👇
https://www.euractiv.com/section/health-consumers/news/link-innovation-clusters-to-boost-biotech-competitiveness-says-commissions-becker/
Developing a Life Sciences Vision for Ireland: Insights from Europe on Health Innovation- Thursday July 10th 2025
Life Sciences Ireland was delighted to attend in the IIEA-Johnson & Johnson webinar, Developing a Life Sciences Vision for Ireland: Insights from Europe on Health Innovation, on July 10, 2025. As Ireland prepares to craft its first national life sciences strategy, this event offered an important platform to explore how aligning healthcare policy with sectoral development can drive innovation, improve patient outcomes, and strengthen Ireland's global competitiveness. Life Sciences Ireland is committed to contributing industry insights and advocating for a coordinated, forward-looking approach that mirrors the success of European counterparts.
To listen to the event 👉ᯤSpotify Link https://open.spotify.com/episode/2ZLGktoA84g0FZH4ZUtaeD?si=QwVMIPcNQPWztE3s7y0leA
EU Life science strategy: a springboard for European life sciences
On the July 2nd the release of the EU Life Science Strategy by the European Commission marks a pivotal moment for healthcare innovation in Europe.
🤔The strategy tackles long-standing competitiveness challenges, aiming to boost clinical trial access, accelerate biotech development, support SMEs, and simplify regulations.
💡Initiatives like the proposed Biotech Act, the Life Sciences Coordination Board, and EUR 300 million in funding for breakthrough treatments show real intent to restore Europe's leadership in life sciences.
🎯The focus on investment, innovation, and access—paired with regulatory improvements—offers a much-needed lifeline for the sector.
It's now time to mobilise these plans into action so European patients benefit from the latest treatments without delay. 🌍💊🔬⚕💉
To read more on this topic check the following Press Release by the EU Commission✍️👇
Life Sciences Ireland Consultation Event June 13th : A Resounding Success in Cork
On June 13th, the Kingsley Hotel in Cork played host to an invaluable consultation event for Life Sciences Ireland, bringing together some of the industry's most insightful minds to discuss the future of the sector. With a packed agenda, dynamic discussions, and critical strategic insights, the event proved to be a vital step in shaping Ireland's life sciences cluster.
A Thoughtfully Orchestrated Event
From the early morning welcome session, complete with lanyard cards and structured seating arrangements, to carefully moderated panel discussions, the day was a masterclass in collaboration. Attendees, including leading industry professionals from the Medical Device, Pharmaceutical, Biopharmaceutical, Healthcare, Education Venture Capital sectors & state enterprise bodies, engaged in forward-thinking dialogue that highlighted industry gaps and explored solutions for a stronger, more resilient life sciences ecosystem.
Key Discussions Driving Industry Growth
A standout feature of the event was the in-depth examination of Life Science cluster models, drawing comparisons between established success stories such as the MassBio cluster in Massachusetts, Spain's BioCat, Cambridge's On Nucleus initiative. With over 1,700 companies fueling MassBio's success and government-backed funding supporting BioCat, discussions delved into the possibilities for Ireland to leverage similar models.
Speakers emphasized the vital role a dedicated cluster organization would play in mitigating economic risks—particularly considering that the majority jobs are currently solely involved in manufacturing and supply chain and 95% financed through foreign direct investment (FDI). By strengthening Ireland's life sciences value chain, such an initiative could bridge skillsets across multiple industry actors, from research at the start of the process to patient outcomes at the end.
The event's impressive lineup included international speakers such as
👉Montse Daban Marín, PhD -Biocat, Catalonia, Spain,
👉Joann Rhodes MBA FRSA- CEO, Health Innovation Research Alliance Northern Ireland,
👉Tony Jones- CEO One Nucleus, Cambridge UK
👉Donagh Kiernan- Tech Alliance Founding Board Member & CEO Tengo Partnering
👉Michael O'Neill-CEO Nomon Bio Ltd
👉Prof Mark Tangney- Head of iEdHub, UCC
ensuring a wealth of perspectives. With funding sources varying between cluster models, questions arose around the risks of membership-fee models versus state-funded initiatives, sparking thought-provoking debate.
A Bold Step Forward
The closing remarks made clear that momentum is building fast. Plans for a not-for-profit Designated Activity Company (DAC) are already in motion to formalize the initiative, and the cluster is set to be activated by the end of 2026. With funding applications open through Enterprise Ireland's Smart Regions: Enterprise Innovation Scheme, stakeholders were encouraged to advocate for the cluster and actively contribute to its growth.
The Life Sciences Ireland consultation event was more than just a meeting of minds—it was a bold declaration that Ireland is ready to move forward, build stronger connections, and position itself as a global life sciences hotspot. With support from industry experts, stakeholders, and advocates, the journey toward a thriving national cluster has truly begun.
